To evaluate the longterm (at least 10 years) characteristics of patients with persistent LUTS after a TURP and continue their medical therapy post-operatively.
INTRODUCTION AND OBJECTIVES:
To evaluate the longterm (at least 10 years) characteristics of patients with persistent LUTS after a TURP and continue their medical therapy post-operatively.
METHODS: A consecutive series of patients with LUTS and Benign prostatic enlargement (BPE) underwent TURP in our center in 2004-2005 and they were then followed up to 2016. Patients were assessed at baseline, 3-, 6-months post-operatively and yearly thereafter with medical history (concomitant medication, reintervention), IPSS, PSA, prostate volume, maximal urinary flow rate (Qmax), post void residual urine (PVR). Reoperation was defined as the requirement of a new TURP to relieve bothersome LUTS. Multivariate logistic regression was used to determine covariates associated with reoperation rate and the Kaplan-Meier curve assessed the time to reoperation. RESULTS: Overall 92 patients were enrolled. Mean age was 79 AE 7 years; mean PSA was 3.2 AE 2.5 ng/ml; mean TRUS volume was 57.5 AE 18.6 ml; mean Qmax was 8.7 AE 4 ml/s; mean IPPS was 23 AE 6 respectively at baseline. Mean follow-up was 140 AE 8 months (median 142 months). Overall 20/92 (21.7%) patients received medical treatment (alpha-blockers and/or 5 alpha-reductase inhibitors) after TURP. 13 patients underwent re-TURP during follow-up (reoperation rate was 14%); out of them 9/13 (69%) received medical treatment for persistent LUTS, while the remaining 4 patients received no additional pharmacological treatment (p ¼ 0.001). Out of the 13 patients treated with re-TURP, 12 (92%) underwent surgery within 5 years of follow-up. Median time to reintervention was 26 months, interquartile range 14/46. The need of LUTS/BPE pharmacological treatment after TURP is an independent risk factor for re-intervention (Odds Ratio 13.93; 95% Confidence Interval 3.63-53.48, p¼ 0.000). Cumulative re-TURP free probability, according to post-operative continuing medical treatment, is showed in Figure 1 . CONCLUSIONS: In our study, a small number of patients (21.7%) still required pharmacological treatment for persistent LUTS. This need was a predictive factor of a re-TURP. Considering that more that 90% of re-TURP were performed during the first 5 years of followup, it is assumable that a follow-up longer than 5 years is not needed in such group of patients.
Source of Funding: none

MP13-07 FINASTERIDE MONOTHERAPY BEFORE TURP: SIGNIFICANT IMPROVEMENT IN EARLY POSTOPERATIVE QUALITY OF LIFE
Ahmed Ali*, Emad Ramadan, Mamdouh El-Hawy, tarek fathelbab, Alayman Hussein, Minia, Egypt; Luay Alshara, Boston, MA; Ahmed Fawzy, Ehab Tawfiek, Minia, Egypt INTRODUCTION AND OBJECTIVES: Introduction: Benign prostatic hyperplasia (BPH) is a common disease affecting men 50 years and older. Treatment options consist of observation, pharmacological treatment, minimally invasive surgery and traditional surgery. Alpha-blockers and 5-alpha-reductase inhibitors are the primary medications used to treat BPH. Transurethral resection of the prostate (TURP) is the gold standard of surgical management of BPH. We sought to evaluate the effect of six weeks of finasteride therapy before TURP on overall surgical outcomes and early postoperative quality of life (QoL).
METHODS: Between June 2011 and August 2013, patients with BPH at the urology department, Minia University Hospital, were randomly assigned to one of two groups: those receiving 5 mg of Finasteride daily for six weeks (group A) and those not receiving finasteride (group B) before TURP. All patients were assessed using a modified validated Arabic version of the International Prostate Symptom Score (IPSS). Intra operative serum hemoglobin concentration and hemoglobin concentration in irrigating fluid were recorded. On the first postoperative day, serum hemoglobin concentration, corrected by postoperative hematocrit values, was evaluated. One month post-surgery, IPSS, storage and voiding subscores and QoL scores were measured. RESULTS: We recruited 115 patients, of whom 98 completed the study. Before surgery, there was no significant difference between the two groups in prostate size, IPSS, maximum urinary flow rate, postvoid residual urine test results or QoL scores. Group A patients had significantly less intraoperative blood loss than group B patients (p¼ 0.001). One month postoperatively, there was no significant difference in IPSS results or voiding and storage subscores between the two groups. However, group A patients showed greater improvement in QoL than group B patients (p ¼ 0.03).
CONCLUSIONS: Short-term finasteride therapy for 6 weeks before TURP reduced intraoperative blood loss and improved quality of life in the early postoperative period. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e155
Source of Funding: None.
MP13-08 SURGEON BEHAVIOR AND SURGICAL MODALITY DRIVE VARIATION IN THE SURGICAL MANAGEMENT OF BPH
Jamal Nabhani*, Vishnukamal Golla, Alan Kaplan, Christopher Saigal, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Identifying actionable variability in care is critical to standardizing treatment and controlling cost. As our institution moves toward bundled payments for benign prostatic hyperplasia (BPH) surgery, it is important to assess the relationship between clinical factors, physician preference, and cost of care.
METHODS: Using time-driven activity-based costing of 358 complete episodes of surgical care for BPH, a variation metric of episodic cost standard deviation divided by mean cost was calculated by surgeon, surgical technique, and prostate size.
RESULTS: Mean episodic cost and standard deviation were $3,529 +/-$570, yielding an overall variation metric of 0.16. Variation metrics ranged from 0.03-0.34 among 18 surgeons (Figure 1) . The variation metric for 288 bipolar transurethral resections of prostate (TURPs) was 0.16, 0.10 for 41 laser vaporization, 0.09 for 20 monopolar TURPs, and 0.08 for 9 open prostatectomies (Figure 2 ). Based on prostate size, the variation metric ranged from 0.17 in prostates < 40 grams, 0.16 for glands between 40-80 grams, and 0.09 for glands > 80 grams. ANOVA with Tukey pairwise comparison revealed a significantly higher (p<0.05) average episodic cost between open prostatectomy and the 3 endoscopic techniques. There was no significant difference in episode cost based on prostate size among endoscopic approaches.
CONCLUSIONS: Variation in the surgical management of BPH appears to be predominantly driven by surgeon behavior and, to a lesser degree, surgical approach, at our institution. Prostate size does not appear to influence variation in the surgical management of BPH. Efforts focused on clarifying the cause of variation at the surgeon-level and based on surgical technique are most likely to yield standardized, high-value care. Photoselective Vaporization of the Prostate (PVP) has been promoted as a valuable alternative to transurethral resection of the Prostate (TURP) and is considered an appropriate and effective treatment in men with moderate to severe LUTS. However the learning curve of this technique has never been evaluated accurately. The objective of this study was to evaluate the learning curve of PVP.
METHODS: Multicenter retrospective study was conducted in the first patients treated with PVP by three operators in 3 different centers (Group 1: 152 patients, Group 2: 112 patients, Group 3: 101 patients). The learning curve was analyzed from the progression in time of quantitative variables: operative time (min), ratios vaporisation time (min)/operative time (%) and delivered energy (Joules)/prostate volume. We also compared the rate of complications (Clavien classification). The relationships between variables were modeled using analysis of covariance (software R 2. 14.2).
RESULTS: The patients' preoperative data differed significantly between each centers in terms of age, prostate volume and IPSS. There was no significate difference in operative time between the three centers (p¼0,06). During the initial 50 cases for each center, a significantly increased in vaporisation time (min)/operative time (%) was observed. 75 patients were necessary to reach the goal of 66 to 80%. (Graphic 1) A significantly increased in energy delivery was observed (this increase appeared to plateau beyond the 50th case in group 3, beyond the 75th case in group 1 and beyond the 100th case in group 2)
